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Abstract
IMPORTANCE Medication review has been proposed to achieve improved use of psychotropic
drugs, but benefits have not been confirmed.
OBJECTIVE To synthesize evidence for focused psychotropic medication review in medication
optimization.
DATA SOURCES Medline, PsycINFO, EMBASE, and CINAHL Plus were searched from inception to
February 2018 using the index terms “drug utilization review” and “psychotropic drugs” and
synonyms. Additional articles were retrieved using citation tracking and reference checking.
STUDY SELECTION Full-length, peer-reviewed articles that reported focused psychotropic
medication reviewwere included. Inclusion was determined against prespecified criteria and
assessed independently.
DATA EXTRACTIONAND SYNTHESIS Study quality was assessed using National Institutes for
Health appraisal tools and informed a structured synthesis of results. Meta-analysis using a random
effects model was conducted.
MAINOUTCOMES ANDMEASURES Change in the number or dosage of psychotropic medications,
change in clinical parameters, change in patient-reported outcomes, and economic data were
collected.
RESULTS A total of 26 studies met the inclusion criteria. Four studies were randomized clinical trials
(n = 712 participants), while the remainder were before-after studies (n = 7844 participants). Most
studies were conducted in elderly individuals, people with dementia, and adults with intellectual
disability. Focused psychotropic medication review is a complex intervention; the professional(s)
involved, target drug, degree of integration with usual care, and participant involvement varied
greatly among the studies. Meta-analysis included 3 studies (n = 652 participants). Psychotropic
medication review was associated with a reduction in prescribing of psychotropic drugs compared
with control (pooled odds ratio, 0.24; 95% CI, 0.14-0.39) in elderly participants with cognitive
impairment living in nursing homes. Before-after studies consistently reported a change in
psychotropic drug prescribing after medication review, regardless of the population. Studies that
reported the effects of psychotropic medication review on clinical outcomes failed to demonstrate
benefit. Economic implications of focused psychotropic medication review were not adequately
assessed. The quality of evidence is poor and studies are at risk of bias.
(continued)
Key Points
Question Does focused psychotropic
medication review promotemedication
optimization?
Findings This systematic review and
meta-analysis found that focused
psychotropic medication review is
associated with reduction in drug
prescribing. Advantages for clinical and
patient-important outcomes have not
been shown.
Meaning More research using
standardizedmedication review
processes and outcomemeasures is
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE Focused psychotropic medication reviewwas associated with a
reduction in prescribing of psychotropic drugs, but has not been shown to improve clinical outcomes
or to provide economic benefit. More robust evidence is needed before programs of focused
psychotropic medication review can be recommended as part of routine care for any patient group.
JAMA Network Open. 2018;1(6):e183750. doi:10.1001/jamanetworkopen.2018.3750
Introduction
The increasing worldwide use of psychotropic drugs and their application beyond licensed
indications has attracted close scrutiny.1-3 At least 1 in 6 adults in the United States is prescribed
psychotropic medication,4 and high levels of psychotropic drug use are demonstrated in several
vulnerable groups, including elderly individuals,5 people with dementia,6 children and adolescents,7
and those with neurodevelopmental disorders, including autism8 and intellectual disability.9,10
Although undoubtedly of benefit to many individuals, psychotropic drugs are associated with
significant adverse drug events that can affect quality of life and result in additional service costs.11,12
Spending on psychotropic drugs continues to grow13,14 and a high rate of nonadherence leads to
significant waste.15
Medication optimization is a broad approach aimed at ensuring the safest and most effective
use of medications.16 The concept has gained traction and has been applied to psychotropic drug
prescribing, for example, in the Centers for Medicare &Medicaid Services’ recent efforts to reduce
inappropriate antipsychotic prescribing in nursing homes.17
Medication optimization encompasses a range of strategies that may be used throughout the
medication pathway, including educational interventions, formularies that identify drugs with the
greatest perceived overall value, consensus guidelines to direct best practices, benchmarking of
prescription rates, and decision aids developed to enable patients to take amore active role in
treatment decisions based on their values and preferences. After a drug has been prescribed,
optimization includes support for adherence andmedication reconciliation. Medication review, a
structured and critical evaluation of medication, might have a role in medication optimization,
maximizing therapeutic efficacy, mitigating adverse events, and identifying opportunities for
decreasing prescribing.18 In this systematic reviewwe describe the content and delivery of focused
psychotropic medication review and synthesize the evidence for its contribution to medication
optimization.
Methods
A literature search was conducted in Medline, PsycINFO, EMBASE, and CINAHL Plus from inception
to February 2018 to identify peer-reviewed original research articles that reported the effect of
focused psychotropic medication review onmedication optimization outcomes. Search terms
included “drug utilization review” (and synonyms) combined with “psychotropic drugs” (and
synonyms) (see eTable 1 in the Supplement for an example of full search strategy). Psychotropic
drugs were defined in accordance with theWorld Health Organization Anatomical Therapeutic
Chemical Classification System.19 Medication reviewwas defined as a structured critical evaluation of
medication with an aim to improve safety, efficacy, or cost-effectiveness. Optimization outcomes
were intentionally broad. Any study design was included and there were no restrictions on
population, setting, language, or date of publication. This study followed the Preferred Reporting
Items for Systematic Reviews andMeta-analyses (PRISMA) reporting guideline. The protocol was
registered prospectively with PROSPERO (registration No. CRD42017077244).
To limit potential confounding, studies were excluded if they reported a comprehensive
medication review (including multiple classes of medication) or conducted a medication review as
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part of amultimodal interventionwhere the effect ofmedication review on reported outcomes could
not be distinguished. Short reports, research letters, dissertations, and conference abstracts were
not included but prompted a search for full-length articles. Reference lists of included studies and
previously published reviews in the field were extensively hand searched to find articles not
identified in the database search. The citations of included articles were identified using Google
Scholar and considered for relevance.
After exclusion of duplicate records, the titles of all articles were screened by one of us (R.S.),
and a randomly selected sample was independently reviewed by another of us (E.B.). They
independently reviewed abstracts of remaining studies (and later selected full text) against inclusion
and exclusion criteria, with any discrepancies resolved by consensus or discussion with a third
member of the research team.
Study quality was rated independently by 2 of us (R.S. and E.B.) using the relevant quality
checklist published by the National Institutes of Health20 along with a descriptive evaluation of the
limitations of each article. Studies received an overall grading of poor, fair, or good quality based on
the proportion of applicable checklist items that were met (poor, <30% of items; fair, 30%-60%;
good, >60%). Results of the quality appraisal were used to inform a structured evidence synthesis,
with higher-quality studies given precedence.
Data were extracted from studies and used to populate summary tables. Type of medication
reviewwas classified according to the Task Force onMedicines Partnership and the National
Collaborative Medicines Management Services Program (level 1, prescription review; level 2,
treatment review; level 3, clinical medication review).18 Outcomeswere grouped according to theme,
allowing comparison between different studies. Measures of psychotropic drug optimization could
include changes in medication-related variables, clinical efficacy or adverse drug events, participant-
reported outcomes, or economic evaluations. Additional data were sought by contacting authors of
included studies, where indicated.
Results were summarized narratively. Numerical data were extracted and, where comparable,
means and 95% CIs were calculated around summary statistics. Odds ratios for comparable
outcomes reported in randomized clinical trials (RCTs) were entered into a meta-analysis using the
metan command in Stata, version 1421 and using a random-effects model. The I2 statistic was used to
estimate statistical heterogeneity between studies.22
Results
The search yielded a total of 9485 articles, of which 27met inclusion criteria (Figure 1). The results of
1 studywere reported in 2 articles.23,24 Four studies were cluster RCTs (n = 712 participants)23-27 and
the remaining 22 were before-after study designs (n = 7844 participants).28-49 Studies were
conducted in North America (15 studies),28,30-33,35-37,39,42,43,46-49 Europe (10
studies)23,25-27,29,38,40,41,44,45 and Australasia (1 study).34 A total of 19 studies23,26-34,36,37,39-41,43,46-48
were conducted in institutional settings and reported psychotropicmedication review of peoplewith
intellectual disability (9 studies; 1054 participants)28-36 or those with dementia (6 studies; 3664
participants).23,37-41 Meta-analysis included 3 studies28,30,34 (n = 652 participants).
Details of included studies are in eTable 2 in the Supplement. When assessed against objective
criteria, most researchwas atmedium to high risk of bias. Keymethodological problems encountered
across studies were single group design, reporting bias, lack of measures of implementation fidelity,
lack of objective and validated outcome measures, short follow-up times, and limited (or absent)
statistical analysis. Several studies made claims that were not supported by the findings.
Content andDelivery of PsychotropicMedication Review
The focused psychotropic medication reviews fell into 3major categories. The first was one-off
medication review, usually undertaken by a single professional and including a single class of
psychotropic drug.23,25,38,40-45 The secondmodel was a longitudinal program of regular medication
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review, often by amultidisciplinary teamwho reviewed the participant’s psychotropic drug regimen
in a series ofmeetings.26-37,39 The third type of focused psychotropicmedication reviewwas 2-stage,
in which those at high risk of suboptimal drug therapy were identified using a rule applied to the
electronic patient record and then directed to clinician medication review.46-49Within this
categorization, the configuration of focused psychotropic medication review varied considerably
from remote review by a third party to detailed medication reviewwith access to the patient’s full
clinical notes and the patient’s direct input to the process (Table 1).18,23-49 Medication reviews were
most often organized according to local protocols, but specific conduct of themedication reviewwas
commonly not reported.
Studies reported review of antipsychotic drugs (9 studies),23,25,29,31,32,37,38,40,41 sedatives and
hypnotics (2 studies),43,49 antidepressants (2 studies),44,45 or several psychotropic drug classes
concomitantly (13 studies).26-28,30,33-36,39,42,46-48 A range of medical and other health professionals
were involved in medication reviews, with the most consistent representation being by clinical
pharmacists. A minority of reviews incorporated involvement of the patient or family or advocate.
Several studies reported standardizedmethods of data collection that were used to inform
medication review, although few used validated instruments to measure clinical variables. Most
focused psychotropic medication reviews relied on implicit decisionmaking and clinician judgment,
rather than explicit measures of drug appropriateness and best practice guidelines.
Figure 1. PRISMA Flowchart
9464 Citations identified (Medline, 3010;
EMBASE, 3371; PsycINFO, 1461;
CINAHL Plus, 1622)




48 Studies for full-text review
27 Studies included in review
(8556 participants)
3 Studies included in meta-analysis
(652 participants)
3043 Duplicates removed
5886 Citations excluded based on title
508 Citations excluded based on abstract
21 Citations excluded after full-text review
3 No medication review intervention
8 Not focused psychotropic review
4 Multimodal intervention
5 No optimization outcome
1 Short report
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Medication-RelatedOutcomes of PsychotropicMedication Review
Ameasure of change in psychotropic drug prescribing after focused psychotropic medication review
was themost consistently reportedmedication-related outcome. Ballard et al,23 Jordan et al,26 and
Patterson et al27 report a significant effect of focused psychotropic medication review in reducing
psychotropic drug prescribing in cognitively impaired elderly residents of nursing homes (pooled
odds ratio, 0.24; 95% CI, 0.14-0.39) (Figure 2).23,25-27 Additional data obtained fromMoncrieff
et al25 showed a nonsignificant tendency to greater change in antipsychotic medication among
adults with severe mental illness undergoing outpatient focused psychotropic medication review
conducted by their usual psychiatrist than among those receiving standard care (odds ratio, 0.38;
95% CI, 0.12-1.19).
One-off focused psychotropic medication reviewwas associated with mean of 34.0% (95% CI,
32.9%-35.2%) of participants having a change in medication prescription
(Figure 3A).29,37,38,40,41,43-45,49 Four before-after studies report the effect of focusedmedication
review on antipsychotic drugs prescribed for behavioral and psychological symptoms of
dementia.37,38,40,41 These reviews, conducted by either a pharmacist37,38,41 or general practitioner,40
were associated with a reduction or discontinuation of antipsychotic drugs in 20% to 61% of
participants.
Gemelli et al43 investigated pharmacist review of sedative and hypnotic medication in elderly
people living in a nursing home. The intervention was associated with dose reduction or
discontinuation in 49% of the sample by follow-up at 3 months.
Two before-after studies addressed the effect on drug prescribing of clinical review of long-term
antidepressant drug therapy in community-dwelling adults. One large Scottish study (N = 2849)
found that 28.5% of individuals taking antidepressants had amedication change after in-person
review by their general practitioner, with most changes being drug discontinuation or dose
reduction.44 A similar study, conducted on amuch smaller scale (N = 32), reported that medication
change followed just above half of the medication reviews conducted by a specialist nurse
prescriber.45
The 4 studies that used electronic prescribing records to identify prescribing that fell outside
defined guidelines to generate alerts, prompting clinician-focused psychotropic medication review,
all report that the process was associated with improved rates of guideline-compliant
prescribing.46-49
Several studies report the association of a program of multidisciplinary medication reviewwith
psychotropic prescribing. In all but 1 case, these studies were conducted before 2000 and focused
on the use of psychotropic drugs for challenging behavior in adults with intellectual disability, most of
whomwere receiving long-term institutional care.28-36 The quality of these studies is poor to fair, yet
together they report results of psychotropic medication review of a relatively homogeneous group
of more than 1000 adults (most with severe to profound intellectual disability and behavior
disturbance living in large institutional facilities), with follow-up of between 6months and 4 years.
Figure 2. Forest Plot Showing Odds of Change in Antipsychotic Medication andOdds of Reduction









Change in psychotropic medication
OR
(95% CI)
60Moncrieff et al,25 2016 0.38 (0.12-1.19)
Reduction in psychotropic medication
277Ballard et al,23 2016 0.17 (0.05-0.60)
43Jordan et al,26 2015 0.22 (0.06-0.87)
334Patterson et al,27  2010 0.26 (0.14-0.49)
Overall effect: I2 = 0.0%; P = .83 0.24 (0.14-0.39)
The size of the data markers is determined by weight
from random-effects analysis. OR indicates odds ratio.
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Figure 3B28,31-35 shows the proportion of participants in these studies undergoing a reduction or
change in psychotropic medication after the review programs, where this metric is given or can be
extrapolated from the published results (mean proportion changing prescription, 57.6%; 95% CI,
53.2%-62.0%). These studies demonstrate the association of focused psychotropic medication
reviewwith medication change in a potentially overmedicated group; most changes were dose
reductions or discontinuations.
Studies that do not report the proportion of participants with medication change still report an
association with either reduction of overall psychotropic prescribing at the group level30,36 or
reduced rates of polypharmacy.28,34 Ellenor and Frisk30 demonstrate a reduction of 37% in
psychotropic prescription items during the course of a 2-year regular medication review and
Marcoux36 found that their process of psychotropic medication reviewwas associated with a mean
dose reduction of 17% in individuals receiving antipsychotic drugs. An exception to these findings is a
more recent study by Dahl et al,39 who report the results of a thoroughmultidisciplinary
psychotropic review in people with dementia who lived in nursing homes. The reviewwas associated
with minimal change in prescribing of any class of psychotropic drug, although interpretation is
limited bymovement of participants into and out of the intervention group.
Psychotropic polypharmacy among participants before and after themedication review
programwas reported by 3 studies.28,30,34 All 3 studies report a substantial reduction in the total
volume of psychotropics associated with focused psychotropic medication review.
Figure 3. Proportion of Participants of Included StudiesWith Change in PsychotropicMedication Prescription
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2849Johnson et al,44 2012
Napolitano et al,45 2012
Reduction in psychotropic medication
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Child et al,38 2012
Gemelli et al,43 2016
Prentice and Wright,41 2014
Morrison,40 2009
Seltzer et al,49 2000
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After one-off medication reviewA




Change in psychotropic medication
80Bisconer et al,28 1995
 Glaser and Morreau,32 1986
Reduction in psychotropic medication
28





Jauernig and Hudson,34 1995
Lepler et al,35 1993
Mean
After medication review programB
A, After one-off medication review. B, After
medication review program. The size of the data
markers is based on the number of participants, and
the error bars indicate 95% CIs.
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Clinical and Patient-RelatedOutcomes of PsychotropicMedication Review
Several disparate clinical outcomes were measured in twelve studies (Table 2).23-30,32-34,42 Ballard
et al23 reported significantly more neuropsychiatric symptoms at 9-month follow-up in people with
dementia receiving antipsychotic review compared with controls (group difference in
Neuropsychiatric Inventory score, 7.37; 95% CI, 1.53-13.22). Furthermore, people receiving the
intervention demonstrated a nominal worsening in health-related quality of life (measured with the
DEMQOL: Dementia Quality of Life measure), which did not reach statistical significance (group
difference, 4.54; 95% CI, –9.26 to 0.19).24 There was no difference in agitation, depression, or
mortality between groups.
Themedication review intervention tested byMoncrieff et al25 was co-designed with people
with severe mental illness with the aim of increasing patient involvement and agency in decision
making regarding antipsychotics. There was no difference in scores on the Decision Self-Efficacy
Scale between those randomized to receive the intervention and those receiving treatment as usual,
suggesting that the focused psychotropic medication review did not improve patients’ confidence
in discussions or decisions about psychotropic medication. Those in the review group demonstrated
a tendency to greater medication adherence but no significant difference was found in other
secondary outcomemeasures of patient satisfaction, attitude toward psychotropic drugs, symptoms
of psychosis, or adverse effects of antipsychotic drugs between groups at follow-up 2 to 4 weeks
after the reviewmeeting. However, fidelity of implementation was poor and the study tested only
feasibility and therefore was not powered to detect effect sizes.
Jordan et al26 reported that moremedication-related problems were identified and addressed
with nurse-led medication review than without. There was no significant difference in change in
psychopathologic characteristics of dementia, behavior changes, or functional ability between
groups during the study period. Longer-term outcomes on patient health or well-being were not
assessed.
Patterson et al27 measured the rate of falls in a group of individuals with dementia who needed
a high level of care. The reductions in inappropriate psychotropic drug use in the intervention group
vs the control group did not translate to a difference in the rate of falls between groups (11.4 falls per
100 person-months in the control group vs 16.3 falls per 100 person-months in intervention group;
P = .09), although the method of recording falls was subject to inaccuracies and the authors note
that the study was underpowered.
Gallimore et al42 reviewed the potential for a focused psychotropic medication review by a
remote pharmacist, conducted several weeks after out-patient psychiatry consultation, to improve
rates of routine adverse drug event monitoring. The focused psychotropic medication review was
associated with an increase in the proportion of participants with up-to-date laboratory monitoring
and significantly reduced the proportion of those at risk of drug-drug interactions but had no effect
on the proportion of participants who were monitored for movement adverse effects. The actual
benefit in terms of adverse drug event rates was not measured.
The study by Bisconer et al28 was the only one, to our knowledge, to report rates of adverse
drug events, albeit with a basic and unvalidatedmethod. The proportion of the cohort with any
physician-observed adverse effect decreased from 14% at baseline to 10% after the review program,
but the small number of participants is a major limitation of this study.
Four studies report change in challenging behavior as a result of antipsychotic review and
reduction programs in institutions for people with intellectual disability.28,30,32,34 These studies
report a decrease or no change in challenging behavior associated with the delivery of the program.
The authors concluded that many psychotropic drugs given in this population can be stopped
without causing further deterioration in behavior.
JAMANetworkOpen | Psychiatry FocusedMedication Review to Optimize Psychotropic Drug Prescribing
JAMA Network Open. 2018;1(6):e183750. doi:10.1001/jamanetworkopen.2018.3750 October 26, 2018 10/18






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































JAMANetworkOpen | Psychiatry FocusedMedication Review to Optimize Psychotropic Drug Prescribing
JAMA Network Open. 2018;1(6):e183750. doi:10.1001/jamanetworkopen.2018.3750 October 26, 2018 11/18
Downloaded From:  by a University College London User  on 10/29/2018
Economic Outcomes of PsychotropicMedication Review
Five studies26,30,36,44,45 reported descriptive cost data in terms of savings made after focused
psychotropic medication review. None of the 5 studies conducted comprehensive economic
evaluation (eTable 3 in the Supplement).
Discussion
Psychotropic medication plays a central role in the treatment of mental disorders, yet remains the
subject of debate. Treatment benefits must be balanced against adverse drug events, which are both
common and distressing.50 Rising rates of prescription of psychotropic drugs are observed
worldwide, despite themodest effect size of these medications for most indications51 and the
increasing availability of and evidence for nonpharmacologic interventions. From an economic
perspective, the estimated US annual expenditure on psychotropic drugs of $30 billion52 must be
viewed in the context of nonadherence rates of up to 65%,53 which contributes to significant waste
of health care resources. On a personal level, patient views and preferences should be respected, but
many report feeling disempowered and excluded from decisions about psychotropic medication.54
Medication optimization aims to address these tensions through a variety of strategies, including
medication review.
Our review of the literature shows that programs of focused psychotropic medication review
have attracted ongoing interest and have been instituted across different settings during the past 4
decades. There is considerable diversity in how focused psychotropic medication review has been
delivered.
Meta-analysis of 3 RCTs demonstrated a significantly greater likelihood of psychotropic drug
reduction with focused psychotropic medication review than with treatment as usual in elderly
individuals with dementia living in nursing homes.23,26,27 Results from several uncontrolled before-
after studies seem to support this finding by reporting an association between medication review
and change in drug prescribing, irrespective of participant group. This finding indicates potential for
improved prescribing after medication review and, although it seems logical that a change in
medication after a critical evaluation will be beneficial, the clinical gains after focused psychotropic
medication review cannot be assumed. Many studies did not measure benefits (or harms) associated
with medication review. A change in drug prescribing is an intermediary outcome that offers only a
crude measure of medication optimization; only 1 study objectively assessed medication
appropriateness against consensus guidelines.27 One RCT reported identification of a greater
number of adverse drug events as a result of focused psychotropic medication review, but not the
resolution of these adverse events.26 Two RCTs failed to demonstrate any benefit of medication
review on clinically meaningful parameters25,27 and 1 RCT reported deterioration in patients’
neuropsychiatric symptoms after medication review and subsequent reduction in drug
prescribing.23,24
Themedication optimization approach is intrinsically patient-centric55 andmedication review
can provide an opportunity to explore patient beliefs and preferences and to reach shared treatment
decisions. However, with 1 notable exception,25 our review highlights a major lack of patient input
and personalization in existing focused psychotropic medication reviews, which represents a
significant barrier to achieving truemedication optimization. This findingmay reflect the age of
several of the studies and a prevailing paternalism in medication decisionmaking in those prescribed
psychotropic drugs.56
The potential for financial savings is a strongmotivator for medication optimization, yet
investigation of the economic implications and resource use of psychotropic medication review has
largely been neglected. Any cost savings from reductions in prescribing and avoidance of adverse
drug events must be offset against the initial outlay of performing themedication review, additional
activity generated (eg, referrals to another health care professional or increased monitoring
mandated by drug changes), and switches to more expensive drugs or preparations. In these terms,
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our findings support calls for more attention to be paid to economic evaluation of
medication review.57,58
Most of the studies included in our review were conducted in elderly individuals, people with
dementia, or adults with intellectual disability, in many cases residing in institutional facilities. People
in these groups are at high risk of suboptimal psychotropic use and overuse andmay lack the capacity
to consent to treatment decisions, yet their underrepresentation in controlled clinical trials leads to
a lack of empirical evidence and data-driven prescribing guidelines. Individual regular and pragmatic
psychotropic medication reviewmay have the most to offer to these groups, where advantages of
medications are less well established and adverse effects are common and idiosyncratic. However, to
realize this potential, the quality and reproducibility of future studies must be improved. Although
recent studies are more robust methodologically, the overall risk of bias is high, with limitations
conferred by both study design and reporting. Future trials should ensure standardized reporting of
the intervention (eg, using the TIDieR [Template for Intervention Description and Replication]
checklist59) and address the feasibility and acceptability of medication review interventions, as their
implementation in routine caremay be complex25 and theymay not always bewelcomed by patients
or their caregivers.60 Moreover, inconsistencies in terminology should be resolved and the concept
of medication review clearly delineated from other attempts to optimize psychotropic
prescribing.61,62
Data in the included studies were not sufficiently detailed to enable subgroup analysis of
medication reviews, beyond grouping interventions by one-off medication review and ongoing
review programs. Multidisciplinary review programs, conductedmostly with participants with
intellectual disability living in institutional care, tended to be associated with the greatest proportion
of participants changingmedication, although this finding could be a function of the high level of
psychotropic use in this group.63
There is no universally accepted standard procedure for medication review.16,64,65 Although
best practice advice and consolidated tools have been developed to guidemedication review66,67
and define potentially inappropriate prescribing,68-70 few of themedication reviews were informed
by a theoretical model. There is the potential for electronic mechanisms, including e-prescribing and
the electronic patient record, to support medication review, in a way which does not yet seem to
have been investigated fully.71
Our findings do not suggest a professional discipline that should lead psychotropic medication
review, although third-party reviews by a professional (usually a pharmacist) external to the usual
teammight be difficult to embed in routine care. As few as one-third of medication
recommendations made by pharmacists are actioned by prescribers,37 and nonprescribers
conducting reviews often report lacking influence,72 highlighting the importance of good
interprofessional communication in complex medication review interventions.
Existing studies and reviews that evaluate the effect of medication review (in other populations
and focused on other drug types) similarly conclude that medication review can influence proximal
medication-related outcomes but demonstrate weak evidence of benefit in clinical and patient
outcomes.66,67,73,74 Despite this finding, medication review is recommended by guidelines as part of
routine care for several groups at high risk of suboptimal prescribing and adverse drug events,
including elderly individuals, those with chronic conditions, and those receiving polypharmacy.16,75
This systematic review andmeta-analysis was of focused psychotropicmedication review. As an
isolated intervention, focusedmedication review has limitations. Comprehensivemedication review,
in which all medications are reviewed simultaneously regardless of indication, can highlight drug-
drug interactions that might bemissed by focusing on psychotropics alone. In practice, however,
psychotropic drug prescribing is often performed by specialists whomay not feel equipped to review
medication for physical health conditions. A treatment review that also incorporates response to
nonpharmacologic interventions is attractive, but might be difficult to protocolize where treatment
aims span different dimensions.
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Strengths and Limitations
To our knowledge, this is the first systematic review to synthesize the evidence for focused
psychotropic medication review. We applied few limits to the search and included varied study
designs. We identified several additional articles through hand searches; this approach is likely to
reflect the nebulous nature of the intervention and a lack of consistent terminology, as well as poor
indexing of older studies. Members of the research team independently appraised studies against
prespecified inclusion criteria and judged study quality using published frameworks. We conducted
meta-analysis and calculated pooled effects where possible.
The deficits of the primary literature limit the strength of our conclusions about the benefits of
psychotropic medication review. Most studies included were uncontrolled and prone to bias and
confounding, and it is difficult to attribute causality in before-after designs. It is impossible to blind
participants and practitioners to the intervention, although blinding might not be essential where
outcomes (eg, prescribing rates) are objective. Clinical outcomes of medication review may only
become apparent after some time; thus, the limited follow-up in the included studies is a major
problem. Diversity in outcomemeasures and reporting precludedmore extensive meta-analysis.
There is potential for publication bias to skew the results of this review and there were insufficient
data to assess this risk statistically. We did not search the gray literature.
Conclusions
Focused psychotropic medication review as a structured and critical evaluation of a patient’s drug
therapy has the potential to contribute to medication optimization. Despite much attention and
incorporation into routine care, the evidence for focused psychotropic medication review as a stand-
alone intervention is weak and it has not been shown that changes in psychotropic prescribing
associated with focused psychotropic medication review translate to improved clinical and patient-
important outcomes. High-quality research is essential before a routine program of focused
psychotropic medication review can be recommended, either in general or special populations.
Standardization of nomenclature, processes, and an agreed common set of outcomes that prioritizes
patient-important measures is needed. This might be achieved with the creation of a national or
international collaborative medication review research network.
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